Clinical presentation of patients with lower limb spasticity undergoing routine treatment with botulinum toxin: baseline findings from an international observational study
DOI:
https://doi.org/10.2340/jrm.v55.4257Keywords:
abobotulinumtoxinA, botulinum toxin A, goal attainment scaling, lower limb spasticity, LegA, rehabilitationAbstract
Objective: Describe how people with lower limb spasticity present for treatment in routine clinical practice.
Methods: Prospective, observational study (Clinicaltrials.gov: NCT04050527) of ambulatory adult patients (≥ 18 years) with unilateral lower limb spasticity (able to take ≥ 5 steps with or without assistance) presenting for routine spasticity management, including treatment with abobotulinumtoxinA.
Results: The study population included 430 adults with lower limb spasticity. Despite their relatively young age (mean ± standard deviation 53.7 ± 13.9 years), only 20% of patients were employed. Most patients had an acquired brain injury due to cerebrovascular disease; 84.1% reported having concomitant upper limb spasticity. Using the Leg Activity Measure, most patients reported no or only mild difficulties in performing hygiene/positioning tasks, while 80.7% had at least mild difficulty with indoor ambulation and 90.5% had at least mild difficulty with walking outdoors. Sensory, communication and/or cognitive impairments were also common. At the first treatment cycle, 50.7% of patients set active function primary goals, including locomotion transferring or standing.
Conclusion: These observations highlight the complexity of presentation that must be considered when setting treatment goals for lower limb spasticity and emphasize the types of impairment and activity (functional) limitations that treating teams may expect to encounter in their patients and should cover in their initial and follow-up assessments.
Downloads
References
Martin A, Abogunrin S, Kurth H, Dinet J. Epidemiological, humanistic, and economic burden of illness of lower limb spasticity in adults: a systematic review. Neuropsychiatr Dis Treat 2014; 10: 111-122.
https://doi.org/10.2147/NDT.S53913 DOI: https://doi.org/10.2147/NDT.S53913
Javed M, Ali MH. Epidemiological burden of lower limb spasticity in adults: a systematic review. J Med Res Innov 2020; 4: e000195.
https://doi.org/10.32892/jmri.195 DOI: https://doi.org/10.32892/jmri.195
Studenski S, Perera S, Wallace D, Chandler JM, Duncan PW, Rooney E, et al. Physical performance measures in the clinical setting. J Am Geriatr Soc 2003; 51: 314-322.
https://doi.org/10.1046/j.1532-5415.2003.51104.x DOI: https://doi.org/10.1046/j.1532-5415.2003.51104.x
Perera S, Patel KV, Rosano C, Rubin SM, Satterfield S, Harris T, et al. Gait speed predicts incident disability: a pooled analysis. J Gerontol A Biol Sci Med Sci 2016; 71: 63-71.
https://doi.org/10.1093/gerona/glv126 DOI: https://doi.org/10.1093/gerona/glv126
Esquenazi, A. Assessment of spasticity and other consequences of the upper motor neuron syndrome affecting the lower limb. In: Spasticity, diagnosis and management. 2nd edition. A. Brashear (editor). New York, NY: Demos Medical Publishing; 2016, Chapter 8, 91-100.
https://doi.org/10.1891/9781617052422.0008 DOI: https://doi.org/10.1891/9781617052422.0008
Soyuer F, Oztürk A. The effect of spasticity, sense and walking aids in falls of people after chronic stroke. Disabil Rehabil 2007; 29: 679-687.
https://doi.org/10.1080/09638280600925860 DOI: https://doi.org/10.1080/09638280600925860
Royal College of Physicians (UK) Spasticity in adults: management using botulinum toxin. National guidelines 2018. Available from: https://www.rcplondon.ac.uk/guidelines-policy/spasticity-adults-management-using-botulinum-toxin.
Simpson DM, Hallett M, Ashman EJ. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Neurology 2016; 86: 1-9. DOI: https://doi.org/10.1097/01.NT.0000483942.53577.94
https://doi.org/10.1212/WNL.0000000000002560 DOI: https://doi.org/10.1212/WNL.0000000000002560
Esquenazi A, Albanese A, Chancellor MB, Elovic E, Segal KR, Simpson DM, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome. Toxicon 2013; 67: 115-128.
https://doi.org/10.1016/j.toxicon.2012.11.025 DOI: https://doi.org/10.1016/j.toxicon.2012.11.025
Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67: 206-207.
https://doi.org/10.1093/ptj/67.2.206 DOI: https://doi.org/10.1093/ptj/67.2.206
Turner-Stokes L, Thu A, Williams H, Casey R, Rose H, Siegert RJ. The Neurological Impairment Scale: reliability and validity as a predictor of functional outcome in neurorehabilitation. Disabil Rehabil 2014; 36: 23-31.
https://doi.org/10.3109/09638288.2013.775360 DOI: https://doi.org/10.3109/09638288.2013.775360
Ashford S, Williams H, Nair A, Orridge S, Turner-Stokes L. Categorisation of goals set using Goal Attainment Scaling for treatment of leg spasticity: a multicentre analysis. Disabil Rehabil 2019; 41: 1925-1930.
https://doi.org/10.1080/09638288.2018.1451927 DOI: https://doi.org/10.1080/09638288.2018.1451927
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011; 20: 1727-1736.
https://doi.org/10.1007/s11136-011-9903-x DOI: https://doi.org/10.1007/s11136-011-9903-x
Ashford SA, Siegert RJ, Williams H, Nair A, Orridge S, Turner-Stokes L. Psychometric evaluation of the leg activity measure (LegA) for outcome measurement in people with brain injury and spasticity. Disabil Rehabil 2021; 43: 976-987.
https://doi.org/10.1080/09638288.2019.1643933 DOI: https://doi.org/10.1080/09638288.2019.1643933
Turner-Stokes L, Disler R, Shaw A, Williams H. Screening for pain in patients with cognitive and communication difficulties: evaluation of the SPIN-screen. Clin Med (Lond) 2008; 8: 393-398.
https://doi.org/10.7861/clinmedicine.8-4-393 DOI: https://doi.org/10.7861/clinmedicine.8-4-393
Jackson D, Horn S, Kersten P, Turner-Stokes L. Development of a pictorial scale of pain intensity for patients with communication impairments: initial validation in a general population. Clin Med (Lond) 2006; 6: 580-585.
https://doi.org/10.7861/clinmedicine.6-6-580 DOI: https://doi.org/10.7861/clinmedicine.6-6-580
Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396: 1204-1222.
Francisco GE, Wissel J, Platz T, Li S. Post-Stroke Spasticity. In: Clinical Pathways in stroke rehabilitation: evidence-based clinical practice recommendations, T. Platz, editor. Cham: Springer International Publishing; 2021, p. 149-173.
https://doi.org/10.1007/978-3-030-58505-1_9 DOI: https://doi.org/10.1007/978-3-030-58505-1_9
Watkins CL, Leathley MJ, Gregson JM, Moore AP, Smith TL, Sharma AK. Prevalence of spasticity post stroke. Clin Rehabil 2002; 16: 515-522.
https://doi.org/10.1191/0269215502cr512oa DOI: https://doi.org/10.1191/0269215502cr512oa
Biering-Soerensen B, Stevenson V, Bensmail D, Grabljevec K, Martínez Moreno M, Pucks-Faes E, et al. European expert consensus on improving patient selection for the management of disabling spasticity with intrathecal baclofen and/or botulinum toxin type A. J Rehabil Med 2022; 54: jrm00241.
https://doi.org/10.2340/16501977-2877 DOI: https://doi.org/10.2340/16501977-2877
Turner-Stokes L, Ashford S, Esquenazi A, Wissel J, Ward AB, Francisco G, et al. A comprehensive person-centered approach to adult spastic paresis: a consensus-based framework. Eur J Phys Rehabil Med 2018; 54: 605-617.
https://doi.org/10.23736/S1973-9087.17.04808-0 DOI: https://doi.org/10.23736/S1973-9087.17.04808-0
Williams G, Singer BJ, Ashford S, Hoare B, Hastings-Ison T, Fheodoroff K, et al. A synthesis and appraisal of clinical practice guidelines, consensus statements and Cochrane systematic reviews for the management of focal spasticity in adults and children. Disabil Rehabil 2022; 44: 509-519.
https://doi.org/10.1080/09638288.2020.1769207 DOI: https://doi.org/10.1080/09638288.2020.1769207
Lee KJ, Tilling KM, Cornish RP, Little RJA, Bell ML, Goetghebeur E, et al. Framework for the treatment and reporting of missing data in observational studies: the treatment and reporting of missing data in observational studies framework. J Clin Epidemiol 2021; 134: 79-88.
https://doi.org/10.1016/j.jclinepi.2021.01.008 DOI: https://doi.org/10.1016/j.jclinepi.2021.01.008
Playford ED, Siegert R, Levack W, Freeman J. Areas of consensus and controversy about goal setting in rehabilitation: a conference report. Clin Rehabil 2009; 23: 334-344.
https://doi.org/10.1177/0269215509103506 DOI: https://doi.org/10.1177/0269215509103506
Levine B, Schweizer TA, O'Connor C, Turner G, Gillingham S, Stuss DT, et al. Rehabilitation of executive functioning in patients with frontal lobe brain damage with goal management training. Front Hum Neurosci 2011; 5: 9.
https://doi.org/10.3389/fnhum.2011.00009 DOI: https://doi.org/10.3389/fnhum.2011.00009
Esquenazi A, Maisonobe P, Sánchez CD, Lysandropoulos A, Ashford S. Impact of patient input on the study execution of an observational study assessing the effectiveness of abobotulinumtoxinA treatment in leg spasticity management in adults (1376). Neurology 2021; 96: 1376.
https://doi.org/10.1016/j.toxicon.2020.11.383 DOI: https://doi.org/10.1016/j.toxicon.2020.11.383
Gupta AD, Chu WH, Howell S, Chakraborty S, Koblar S, Visvanathan R, et al. A systematic review: efficacy of botulinum toxin in walking and quality of life in post-stroke lower limb spasticity. Syst Rev 2018; 7: 1.
https://doi.org/10.1186/s13643-017-0670-9 DOI: https://doi.org/10.1186/s13643-017-0670-9
Ward AB, Wissel J, Borg J, Ertzgaard P, Herrmann C, Kulkarni J, et al. Functional goal achievement in post-stroke spasticity patients: the BOTOX® Economic Spasticity Trial (BEST). J Rehabil Med 2014; 46: 504-513.
https://doi.org/10.2340/16501977-1817 DOI: https://doi.org/10.2340/16501977-1817
Portelli R, Lowe D, Irwin P, Pearson M, Rudd AG. Institutionalization after stroke. Clin Rehabil 2005; 19: 97-108.
https://doi.org/10.1191/0269215505cr822oa DOI: https://doi.org/10.1191/0269215505cr822oa
Hardy SE, Kang Y, Studenski SA, Degenholtz HB. Ability to walk 1/4 mile predicts subsequent disability, mortality, and health care costs. J Gen Intern Med 2011; 26: 130-135
https://doi.org/10.1007/s11606-010-1543-2 DOI: https://doi.org/10.1007/s11606-010-1543-2
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Alberto Esquenazi, Richard D. Zorowitz, Stephen Ashford, Pascal Maisonobe, Simon Page, Jorge Jacinto
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized JRM contents is available freely online. The Foundation for Rehabilitation Medicine owns the copyright for all material published until volume 40 (2008), as from volume 41 (2009) authors retain copyright to their work and as from volume 49 (2017) the journal has been published Open Access, under CC-BY-NC licences (unless otherwise specified). The CC-BY-NC licenses allow third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
From 2024, articles are published under the CC-BY licence. This license permits sharing, adapting, and using the material for any purpose, including commercial use, with the condition of providing full attribution to the original publication.
